An integrative approach for building personalized gene regulatory networks for precision medicine.
Monique G P van der WijstDylan H de VriesHarm BruggeHarm-Jan WestraLude FrankePublished in: Genome medicine (2018)
Only a small fraction of patients respond to the drug prescribed to treat their disease, which means that most are at risk of unnecessary exposure to side effects through ineffective drugs. This inter-individual variation in drug response is driven by differences in gene interactions caused by each patient's genetic background, environmental exposures, and the proportions of specific cell types involved in disease. These gene interactions can now be captured by building gene regulatory networks, by taking advantage of RNA velocity (the time derivative of the gene expression state), the ability to study hundreds of thousands of cells simultaneously, and the falling price of single-cell sequencing. Here, we propose an integrative approach that leverages these recent advances in single-cell data with the sensitivity of bulk data to enable the reconstruction of personalized, cell-type- and context-specific gene regulatory networks. We expect this approach will allow the prioritization of key driver genes for specific diseases and will provide knowledge that opens new avenues towards improved personalized healthcare.
Keyphrases
- single cell
- healthcare
- genome wide
- rna seq
- gene expression
- end stage renal disease
- copy number
- genome wide identification
- high throughput
- dna methylation
- chronic kidney disease
- ejection fraction
- induced apoptosis
- electronic health record
- newly diagnosed
- big data
- peritoneal dialysis
- air pollution
- emergency department
- case report
- prognostic factors
- genome wide analysis
- network analysis
- bone marrow
- machine learning
- transcription factor
- signaling pathway
- climate change
- cell proliferation
- patient reported outcomes
- blood flow
- artificial intelligence